[go: up one dir, main page]

DK3209295T3 - Fremgangsmåder til behandling af øjenlidelser - Google Patents

Fremgangsmåder til behandling af øjenlidelser Download PDF

Info

Publication number
DK3209295T3
DK3209295T3 DK15852340.7T DK15852340T DK3209295T3 DK 3209295 T3 DK3209295 T3 DK 3209295T3 DK 15852340 T DK15852340 T DK 15852340T DK 3209295 T3 DK3209295 T3 DK 3209295T3
Authority
DK
Denmark
Prior art keywords
procedures
treatment
eye disorders
disorders
eye
Prior art date
Application number
DK15852340.7T
Other languages
English (en)
Other versions
DK3209295T4 (da
Inventor
Douglas Michael Ackermann Jr
James Loudin
Kenneth J Mandell
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3209295(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Application granted granted Critical
Publication of DK3209295T3 publication Critical patent/DK3209295T3/da
Publication of DK3209295T4 publication Critical patent/DK3209295T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
DK15852340.7T 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser DK3209295T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07
PCT/US2015/056273 WO2016064759A1 (en) 2014-10-20 2015-10-19 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
DK3209295T3 true DK3209295T3 (da) 2021-03-01
DK3209295T4 DK3209295T4 (da) 2024-02-26

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20212556.3T DK3848028T5 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser
DK15852340.7T DK3209295T4 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20212556.3T DK3848028T5 (da) 2014-10-20 2015-10-19 Fremgangsmåder til behandling af øjenlidelser

Country Status (21)

Country Link
US (14) US9504645B2 (da)
EP (3) EP4413974A3 (da)
JP (3) JP6873906B2 (da)
KR (2) KR102601505B1 (da)
CN (3) CN107106542B (da)
AU (2) AU2015336216B2 (da)
BR (2) BR112017008097B1 (da)
CA (1) CA2965129C (da)
DK (2) DK3848028T5 (da)
EA (1) EA035335B1 (da)
ES (2) ES2986830T3 (da)
FI (1) FI3848028T3 (da)
IL (3) IL318427A (da)
MX (2) MX392383B (da)
MY (1) MY186870A (da)
PH (1) PH12017500602A1 (da)
PL (1) PL3848028T3 (da)
PT (2) PT3848028T (da)
SG (2) SG11201703135XA (da)
WO (1) WO2016064759A1 (da)
ZA (1) ZA201703467B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4413974A3 (en) 2014-10-20 2024-10-09 Oyster Point Pharma, Inc. Methods of treating ocular conditions
PT3439661T (pt) * 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
EP4142734B1 (en) 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
DE60209929T2 (de) 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
MX2007004495A (es) 2004-10-15 2007-05-10 Pfizer Prod Inc Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
EP1809237B1 (en) * 2004-11-09 2008-12-31 Novagali Pharma SA Ophthalmic oil-in-water type emulsion with stable positive zeta potential
AU2006226509A1 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
WO2007025249A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
WO2007038686A2 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
EA016494B1 (ru) * 2007-02-02 2012-05-30 Пфайзер Продактс Инк. (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ
EP2322168A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2010028033A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
KR20110098763A (ko) 2008-12-01 2011-09-01 타가셉트 인코포레이티드 (ｒ)-5-((ｅ)-2-(피롤리딘-3-일비닐)피리미딘의 합성 및 그의 신규한 염 형태
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
EP2720719A4 (en) * 2011-06-15 2015-12-09 Glaxosmithkline Ip No 2 Ltd METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
RU2014103098A (ru) * 2011-06-30 2015-08-10 Торэй Индастриз, Инк. Противозудный агент
EA034964B1 (ru) * 2011-10-20 2020-04-13 Новартис Аг Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
EP2786142A4 (en) * 2011-11-30 2015-07-22 Diagnostear Ltd DIAGNOSIS OF THE DRY EYE
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
EP2968368B1 (en) 2013-03-15 2017-08-09 Glia LLC Cranial delivery of pharmaceuticals
HK1220934A1 (zh) 2013-04-19 2017-05-19 Oculeve, Inc. 鼻刺激装置和方法
EP4413974A3 (en) 2014-10-20 2024-10-09 Oyster Point Pharma, Inc. Methods of treating ocular conditions
PT3439661T (pt) 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions

Also Published As

Publication number Publication date
MY186870A (en) 2021-08-26
AU2020213351A1 (en) 2020-08-27
KR20170086040A (ko) 2017-07-25
US11903942B2 (en) 2024-02-20
US20250255865A1 (en) 2025-08-14
DK3209295T4 (da) 2024-02-26
EP3848028A1 (en) 2021-07-14
MX2022005888A (es) 2022-06-14
WO2016064759A1 (en) 2016-04-28
US11903941B2 (en) 2024-02-20
US20160106745A1 (en) 2016-04-21
BR122022025737B1 (pt) 2023-12-26
EP3848028B1 (en) 2024-05-29
CN107106542A (zh) 2017-08-29
ES2848977T3 (es) 2021-08-13
US11903943B2 (en) 2024-02-20
US11911380B2 (en) 2024-02-27
US20230226053A1 (en) 2023-07-20
IL293188B2 (en) 2025-06-01
AU2020213351B2 (en) 2023-04-06
MX392383B (es) 2025-03-24
EP3209295A1 (en) 2017-08-30
SG11201703135XA (en) 2017-05-30
DK3848028T5 (da) 2025-01-20
ES2986830T3 (es) 2024-11-12
EP3209295B2 (en) 2023-12-06
ZA201703467B (en) 2023-12-20
CN111956650A (zh) 2020-11-20
US20170239244A1 (en) 2017-08-24
DK3848028T3 (da) 2024-08-26
AU2015336216B2 (en) 2020-05-21
BR112017008097B1 (pt) 2023-03-28
IL293188A (en) 2022-07-01
KR102601505B1 (ko) 2023-11-14
ES2848977T5 (es) 2024-06-06
US9597284B2 (en) 2017-03-21
US20240173318A1 (en) 2024-05-30
FI3848028T3 (fi) 2024-08-21
EP4413974A2 (en) 2024-08-14
JP2023024574A (ja) 2023-02-16
SG10202011669PA (en) 2020-12-30
US20160106744A1 (en) 2016-04-21
CN111956650B (zh) 2024-06-04
CN111956803A (zh) 2020-11-20
EA201790893A1 (ru) 2018-01-31
EP3848028B9 (en) 2024-10-16
CN107106542B (zh) 2020-05-08
KR20230042144A (ko) 2023-03-27
MX2017005064A (es) 2018-02-23
EP4413974A3 (en) 2024-10-09
US20200246336A1 (en) 2020-08-06
PT3848028T (pt) 2024-09-20
US20160106665A1 (en) 2016-04-21
IL293188B1 (en) 2025-02-01
EP3209295A4 (en) 2018-05-23
BR112017008097A2 (pt) 2018-02-20
EA035335B1 (ru) 2020-05-28
AU2015336216A1 (en) 2017-06-08
PL3848028T3 (pl) 2024-11-18
JP6873906B2 (ja) 2021-05-19
US9504644B2 (en) 2016-11-29
US20250235449A1 (en) 2025-07-24
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
JP7502404B2 (ja) 2024-06-18
US20230226054A1 (en) 2023-07-20
JP2021038250A (ja) 2021-03-11
IL318427A (en) 2025-03-01
KR102511955B1 (ko) 2023-03-22
IL251769A0 (en) 2017-06-29
US10456396B2 (en) 2019-10-29
CA2965129C (en) 2024-03-12
PH12017500602A1 (en) 2017-09-04
US20250275963A1 (en) 2025-09-04
US11224598B2 (en) 2022-01-18
EP3209295B1 (en) 2020-12-09
PT3209295T (pt) 2021-02-05
US9532944B2 (en) 2017-01-03
US20230226052A1 (en) 2023-07-20
US9504645B2 (en) 2016-11-29
IL251769B (en) 2022-06-01
JP2017531044A (ja) 2017-10-19
CA2965129A1 (en) 2016-04-28
CN111956803B (zh) 2025-10-31
JP7257371B2 (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
IL247452A0 (en) Compounds for treatment of complement mediated disorders
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3393579T3 (da) Øjenbehandlingssystem
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser